Skip to main content

Advertisement

Table 1 Antimicrobial susceptibility test and molecular results for all ceftazidime-resistant P. aeruginosa isolates (n = 26) responsible of bloodstream infections (BSI)

From: Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase

Isolates MIC of agents (μg/ml) a Type of enzymes produced
  PIP TZP CAZ FEP ATM IMP MEM CIP AMK GEN  
338/98 > 256 > 256 > 256 128 > 256 8 32 > 32 64 > 256 AmpC, PER-1
LS034/99 > 256 > 256 > 256 > 256 > 256 > 32 > 32 > 32 64 > 256 AmpC, PER-1
140/99 > 256 > 256 > 256 64 > 256 16 32 > 32 64 > 256 AmpC, PER-1
47/00 > 256 > 256 > 256 128 > 256 16 8 > 32 16 > 256 AmpC, PER-1
324/00 > 256 > 256 > 256 > 256 > 256 > 32 16 > 32 16 > 256 AmpC, PER-1
A360/00 > 256 > 256 > 256 > 256 > 256 > 32 16 > 32 16 > 256 AmpC, PER-1
527/00 > 256 > 256 > 256 > 256 > 256 > 32 32 > 32 16 > 256 AmpC, PER-1
2126/01 > 256 > 256 > 256 64 > 256 16 8 > 32 32 > 256 AmpC, PER-1
A150/02 > 256 > 256 > 256 48 > 256 > 32 32 > 32 > 256 > 256 AmpC, PER-1
299/98 > 256 128 32 64 32 2 2 0.094 4 8 AmpC
77/99 > 256 64 64 16 64 4 2 0.5 8 8 AmpC
251/00 > 256 128 16 32 16 2 4 > 32 128 > 256 AmpC
746/00 > 256 64 16 64 16 8 8 > 32 96 > 256 AmpC
2497/01 > 256 128 16 128 16 2 1 0.125 8 > 256 AmpC
2544/01 256 64 32 128 64 16 2 0.5 16 > 256 AmpC
A372/02 64 32 16 32 32 0.5 0.5 > 32 32 > 256 AmpC
A480/02 > 256 64 64 16 8 > 32 16 0.094 1 4 AmpC
659/02 96 32 32 16 16 1 0.5 > 32 8 > 256 AmpC
694/02 128 64 16 8 16 4 8 > 32 16 > 256 AmpC
A276/03b 64 32 32 16 16 1 0.5 > 32 16 > 256 AmpC
A562/03b 64 16 32 16 16 1 0.5 > 32 16 > 256 AmpC
A173/03b 32 4 32 16 16 1 0.5 > 32 4 8 AmpC
A189/03 c 32 16 32 16 8 1 0.5 > 32 8 > 256 AmpC
A590/03 > 256 128 64 8 64 32 8 0.125 0.5 2 AmpC
A424/04 > 256 64 64 4 32 4 2 0.094 1 4 AmpC
A567/04 c 128 64 64 16 16 1 0.5 0.125 0.5 2 AmpC
  1. a MIC values were obtained using the Etest method (AB Biodisk). Abbreviations of antimicrobial agents and breakpoints for susceptibility (S) and resistance (R) are given: PIP, piperacillin (S ≤ 64, R ≥ 128); TZP, piperacillin plus tazobactam (S ≤ 64, R ≥ 128); CAZ, ceftazidime (S ≤ 8, R ≥ 32); FEP, cefepime (S ≤ 8, R ≥ 32); ATM, aztreonam (S ≤ 8, R ≥ 32); IPM, imipenem (S ≤ 4, R ≥ 16); MEM, meropenem (S ≤ 4, R ≥ 16); CIP, ciprofloxacin (S ≤ 1, R ≥ 4); AMK, amikacin (S ≤ 16, R ≥ 64); GEN, gentamicin (S ≤ 4, R ≥ 16).
  2. b These strains caused three different BSI in the same patient.
  3. c Only microbiological data were available. Therefore, these 2 cases were excluded from statistical analysis of demographic data, risk factors and treatment outcome.